These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 34229570)
1. Comparative analysis of SARS-CoV-2 envelope viroporin mutations from COVID-19 deceased and surviving patients revealed implications on its ion-channel activities and correlation with patient mortality. Rizwan T; Kothidar A; Meghwani H; Sharma V; Shobhawat R; Saini R; Vaishnav HK; Singh V; Pratap M; Sihag H; Kumar S; Dey JK; Dey SK J Biomol Struct Dyn; 2022; 40(20):10454-10469. PubMed ID: 34229570 [TBL] [Abstract][Full Text] [Related]
2. Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week. Troyano-Hernáez P; Reinosa R; Holguín Á Viruses; 2021 Feb; 13(2):. PubMed ID: 33557213 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic perspective of missense mutations of ORF3a protein of SARS-CoV-2. Hassan SS; Attrish D; Ghosh S; Choudhury PP; Roy B Virus Res; 2021 Jul; 300():198441. PubMed ID: 33940003 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection alkalinizes the ERGIC and lysosomes through the viroporin activity of the viral envelope protein. Wang WA; Carreras-Sureda A; Demaurex N J Cell Sci; 2023 Mar; 136(6):. PubMed ID: 36807531 [TBL] [Abstract][Full Text] [Related]
5. Patch-clamp studies and cell viability assays suggest a distinct site for viroporin inhibitors on the E protein of SARS-CoV-2. Breitinger U; Sedky CA; Sticht H; Breitinger HG Virol J; 2023 Jul; 20(1):142. PubMed ID: 37422646 [TBL] [Abstract][Full Text] [Related]
7. SARS-Cov-2 ORF3a: Mutability and function. Bianchi M; Borsetti A; Ciccozzi M; Pascarella S Int J Biol Macromol; 2021 Feb; 170():820-826. PubMed ID: 33359807 [TBL] [Abstract][Full Text] [Related]
8. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray. Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808 [TBL] [Abstract][Full Text] [Related]
9. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor. Dey D; Borkotoky S; Banerjee M Comput Biol Med; 2020 Dec; 127():104063. PubMed ID: 33126128 [TBL] [Abstract][Full Text] [Related]
10. Proteo-Genomic Analysis of SARS-CoV-2: A Clinical Landscape of Single-Nucleotide Polymorphisms, COVID-19 Proteome, and Host Responses. Tushir S; Kamanna S; Nath SS; Bhat A; Rose S; Aithal AR; Tatu U J Proteome Res; 2021 Mar; 20(3):1591-1601. PubMed ID: 33555895 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors. Cao Y; Yang R; Lee I; Zhang W; Sun J; Wang W; Meng X Protein Sci; 2021 Jun; 30(6):1114-1130. PubMed ID: 33813796 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Viroporin E Induces Ca López-Vázquez S; Villalobos C; Núñez L Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928009 [TBL] [Abstract][Full Text] [Related]
14. Mutational insights into the envelope protein of SARS-CoV-2. Rahman MS; Hoque MN; Islam MR; Islam I; Mishu ID; Rahaman MM; Sultana M; Hossain MA Gene Rep; 2021 Mar; 22():100997. PubMed ID: 33319124 [TBL] [Abstract][Full Text] [Related]
15. Exhaustive mutational analysis of severe acute respiratory syndrome coronavirus 2 ORF3a: An essential component in the pathogen's infectivity cycle. Benazraf A; Arkin IT Protein Sci; 2023 Jan; 32(1):e4528. PubMed ID: 36468608 [TBL] [Abstract][Full Text] [Related]
16. Distinct motifs in the E protein are required for SARS-CoV-2 virus particle formation and lysosomal deacidification in host cells. Miura K; Suzuki Y; Ishida K; Arakawa M; Wu H; Fujioka Y; Emi A; Maeda K; Hamajima R; Nakano T; Tenno T; Hiroaki H; Morita E J Virol; 2023 Oct; 97(10):e0042623. PubMed ID: 37830820 [TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Envelope (E) protein interacts with PDZ-domain-2 of host tight junction protein ZO1. Shepley-McTaggart A; Sagum CA; Oliva I; Rybakovsky E; DiGuilio K; Liang J; Bedford MT; Cassel J; Sudol M; Mullin JM; Harty RN PLoS One; 2021; 16(6):e0251955. PubMed ID: 34106957 [TBL] [Abstract][Full Text] [Related]
18. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Nagy Á; Pongor S; Győrffy B Int J Antimicrob Agents; 2021 Feb; 57(2):106272. PubMed ID: 33347989 [TBL] [Abstract][Full Text] [Related]
19. Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients. Laskar R; Ali S Chem Biol Interact; 2021 Sep; 347():109598. PubMed ID: 34303694 [TBL] [Abstract][Full Text] [Related]
20. Genome-wide association analysis of COVID-19 mortality risk in SARS-CoV-2 genomes identifies mutation in the SARS-CoV-2 spike protein that colocalizes with P.1 of the Brazilian strain. Hahn G; Wu CM; Lee S; Lutz SM; Khurana S; Baden LR; Haneuse S; Qiao D; Hecker J; DeMeo DL; Tanzi RE; Choudhary MC; Etemad B; Mohammadi A; Esmaeilzadeh E; Cho MH; Li JZ; Randolph AG; Laird NM; Weiss ST; Silverman EK; Ribbeck K; Lange C Genet Epidemiol; 2021 Oct; 45(7):685-693. PubMed ID: 34159627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]